Pancreatic ductal adenocarcinoma (PDAC) is the most common malignancy of the pancreas, representing the 4th to 5th most common cause of cancer-related deaths. This highly aggressive disease is difficult to treat. To this day, the only chance for cure is a complete surgical removal of the tumor.
However, since 80-90% of the cases are surgically incurable at the time of diagnosis, the 5-year survival rates are at a disheartening 6%. This is the lowest for all solid tumors, making PDAC a disease with a major socioeconomic impact. Despite our advancing knowledge of the tumor biology, no breakthrough in patient treatment has been achieved over the past decades. The CAM-PaC project wants to change this:
Our main objective is to systematically characterize and validate new targets for therapeutic intervention by developing novel cellular and animal models and integrating large-scale metabolic and transcriptomic data obtained from these models. Our research will pave the way for new approaches that might ultimately lead to new treatment options aimed at reducing patients' suffering and improving survival rates.